| Title |
Effectiveness and Tolerability of Second-Line Therapy with Vildagliptin Versus Other Oral Agents in Type 2 Diabetes (EDGE): Post Hoc Sub-Analysis of Bulgarian Data
|
|---|---|
| Published in |
Diabetes Therapy, September 2014
|
| DOI | 10.1007/s13300-014-0083-x |
| Pubmed ID | |
| Authors |
Zdravko Kamenov |
| Abstract |
Metformin is an established first-line treatment for type 2 diabetes mellitus (T2DM) patients but intensification of oral anti-diabetic therapy is usually required over time. The effectiveness of diabetes control with vildaGliptin and vildagliptin/mEtformin (EDGE) study compared effectiveness and safety of vildagliptin and other oral anti-diabetic drugs (OAD) in 45,868 patients worldwide with inadequately controlled T2DM by monotherapy under real-life conditions. Here, we present effectiveness results for patients receiving vildagliptin (vildagliptin cohort) or another OAD (comparator cohort) add-on to monotherapy in Bulgaria. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 5% |
| Unknown | 19 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 4 | 20% |
| Other | 3 | 15% |
| Researcher | 3 | 15% |
| Student > Ph. D. Student | 3 | 15% |
| Student > Doctoral Student | 2 | 10% |
| Other | 4 | 20% |
| Unknown | 1 | 5% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 11 | 55% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 10% |
| Agricultural and Biological Sciences | 2 | 10% |
| Nursing and Health Professions | 2 | 10% |
| Psychology | 1 | 5% |
| Other | 1 | 5% |
| Unknown | 1 | 5% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 September 2014.
All research outputs
#14,201,088
of 22,764,165 outputs
Outputs from Diabetes Therapy
#443
of 1,013 outputs
Outputs of similar age
#130,173
of 251,975 outputs
Outputs of similar age from Diabetes Therapy
#5
of 10 outputs
Altmetric has tracked 22,764,165 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,013 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 251,975 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 10 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.